论文部分内容阅读
目前对卵巢癌的治疗原则是以手术为主,辅以化疗等综合治疗。随着联合化疗方案广泛和标准化应用,化疗效果显著提高。但随之而来的肿瘤细胞的原发性和/或继发性耐药现象成为临床治疗的障碍。卵巢癌化疗效果欠佳,关键原因是卵巢癌细胞对化疗药物铂类耐药。顺铂的耐药机制很复杂,各个环节的异常均有可能产生耐药,耐药的卵巢癌细胞最终表现为细胞调亡明显减少[1]。因此探索耐药机制是解决耐药问题,改善化疗效果的关键。随着生命科学的飞速发展,分子生物学技术的不断改进,从基因水平去研究耐药机制已成为热点。
The current treatment of ovarian cancer is based on the principle of surgery, combined with chemotherapy and other comprehensive treatment. With the extensive and standardized combination of chemotherapy regimens, the effect of chemotherapy is significantly improved. However, the attendant primary and / or secondary drug resistance of tumor cells has become an obstacle to clinical treatment. Chemotherapy of ovarian cancer is not effective, the key reason is that ovarian cancer cells on the chemotherapy drug platinum resistance. Cisplatin resistance mechanism is very complex, all aspects of the abnormalities are likely to produce resistance, drug-resistant ovarian cancer cells eventually showed a significant reduction in apoptosis [1]. Therefore, to explore the mechanism of drug resistance is to solve the problem of resistance, the key to improving the efficacy of chemotherapy. With the rapid development of life sciences and the continuous improvement of molecular biology techniques, it has become a hot spot to study the mechanism of resistance from the genetic level.